While FGFR1 alone resulted in very few palpable tumors with a long latency, FGFR1 is often amplified with other oncogenes such as c-MYC and CCND1 in breast cancer, which are downstream targets of the canonical Wnt signaling pathway [16]. Here, FGFR1 is linked to breast carcinoma.